BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21532850)

  • 1. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.
    Yang MA; Lee J; Choi EH; Lee HJ
    J Korean Med Sci; 2011 May; 26(5):612-8. PubMed ID: 21532850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.
    Grisaru-Soen G; Lerner-Geva L; Keller N; Berger H; Passwell JH; Barzilai A
    Pediatr Infect Dis J; 2000 Oct; 19(10):959-63. PubMed ID: 11055596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
    Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
    Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
    Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas Bacteremia in Children: Clinical and Microbiologic Features and Risk Factors of Mortality: A Retrospective Cohort Study.
    Abu Shqara R; Kassis I; Damouni Shalabi R; Dabaja Younis H
    Pediatr Infect Dis J; 2023 Jun; 42(6):479-484. PubMed ID: 36854120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.
    Peña C; Gómez-Zorrilla S; Suarez C; Dominguez MA; Tubau F; Arch O; Oliver A; Pujol M; Ariza J
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2791-7. PubMed ID: 22552893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.
    Dantas RC; Ferreira ML; Gontijo-Filho PP; Ribas RM
    J Med Microbiol; 2014 Dec; 63(Pt 12):1679-1687. PubMed ID: 25261066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in
    Kang JS; Moon C; Mun SJ; Lee JE; Lee SO; Lee S; Lee SH
    J Korean Med Sci; 2021 Nov; 36(43):e273. PubMed ID: 34751008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
    Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
    Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
    Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
    J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
    Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five-year review of Pseudomonas aeruginosa bacteremia in children hospitalized at a single center in southern China.
    Zhang Q; Smith JC; Zhu Q; Guo Z; MacDonald NE
    Int J Infect Dis; 2012 Aug; 16(8):e628-32. PubMed ID: 22709682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological features and risk factors for mortality in Pseudomonas aeruginosa bacteremia in children.
    Rosanova MT; Mussini MS; Arias AP; Sormani MI; Mastroianni A; García ME; Reijtman V; Sarkis C
    Arch Argent Pediatr; 2019 Apr; 117(2):128-131. PubMed ID: 30869488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
    Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
    BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
    Suárez C; Peña C; Tubau F; Gavaldà L; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
    J Infect; 2009 Apr; 58(4):285-90. PubMed ID: 19297028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.
    Motbainor H; Bereded F; Mulu W
    BMC Infect Dis; 2020 Jan; 20(1):92. PubMed ID: 32000693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
    Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
    Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa bacteremia after burn injury: the impact of multiple-drug resistance.
    Theodorou P; Thamm OC; Perbix W; Phan VT
    J Burn Care Res; 2013; 34(6):649-58. PubMed ID: 23817000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.